Prostate cancer associated HIP1 interacting long non-coding RNA (PCHILR)

Prostate cancer associated HIP1 interacting long non-coding RNA (PCHILR) is a novel long non-coding RNA mapped to chromosome 16 (synonym PCLN16)[4][6]. It is strongly upregulated in prostate cancer tissues and androgen receptor-dependent prostate cancer cell lines[1][5][7]. Mechanistically, PCHILR augments androgen receptor (AR) signaling by binding to the HIP1 transcript, reducing HIP1 degradation. HIP1 functions as a critical AR regulator, and the stabilization of HIP1 increases AR pathway activation, driving tumor growth and progression[1][2]. Experimental silencing of PCHILR suppresses AR signaling and reduces prostate cancer tumor growth in preclinical models[1][2][5]. This evidence supports its role as an oncogene and potential therapeutic target and biomarker in prostate cancer. There are no drugs or clinical modulators currently known to specifically target PCHILR, but RNA-based therapies directed at lncRNAs are in development[1][2][5]. No safety issues specific to PCHILR targeting have emerged in the literature.

Other names

PCLN16prostate cancer lncRNA at chromosome 16